C
Carasent ASA
OSE:CARA
Carasent ASA
OSE:CARA
Price:
18.35 NOK
Updated:
May 29, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
57
Current
35.5
Median
12.8
Industry
Higher
than median
Higher
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=57
Enterprise Value
/
990.4m
EBITDA
17.4m
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| NO |
C
|
Carasent ASA
OSE:CARA
|
1.3B NOK | 57 | |
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
32.8B USD | 62.2 | |
| US |
|
Cerner Corp
NASDAQ:CERN
|
27.9B USD | 19.6 | |
| US |
|
Change Healthcare Inc
NASDAQ:CHNG
|
9B USD | 16.5 | |
| AU |
|
Pro Medicus Ltd
ASX:PME
|
11.8B AUD | 116.7 | |
| JP |
|
M3 Inc
TSE:2413
|
1T JPY | 12.2 | |
| US |
|
Doximity Inc
NYSE:DOCS
|
5.4B USD | 25.2 | |
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
4.7B USD | -129 | |
| SE |
|
Sectra AB
STO:SECT B
|
46.3B SEK | -71.8 | |
| US |
|
Vocera Communications Inc
NYSE:VCRA
|
2.8B USD | 264.4 | |
| US |
|
Goodrx Holdings Inc
NASDAQ:GDRX
|
2.7B USD | 36.3 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
24.6
2-Years Forward
EV/EBITDA
18.7
3-Years Forward
EV/EBITDA
12.1
You don't have any saved screeners yet
